According to a recent Future Market Insights report, the global Hyperammonemia Treatment market size is expected to be worth US$ 1,318.05 million in 2023 and US$ 2,100 million by 2033, at a CAGR of 4.77%.
The rising prevalence of urea cycle illnesses, as well as substantial research and development, are propelling the Hyperammonemia Treatment market forward. Increased infrastructural development and government support are projected to influence market demand. The growing public awareness of hyperammonemia, as well as the increasing number of innovative diagnostic technologies, are propelling the hyperammonemia Treatment market forward.
For more insights into the market, request a sample of this report@ https://www.futuremarketinsights.com/reports/sample/rep-gb-16383
Furthermore, research and development studies emphasising the genetic characteristics of Hyperammonemia would help market participants align their product development, thereby contributing to market expansion. Nonetheless, long-term Treatment challenges, drug production challenges, and diagnostic challenges are expected to limit the global Hyperammonemia Treatment market’s growth.
Key Takeaways from the Market Study
- The global hyperammonemia therapeutic market is expected to grow 1.6x between 2023 and 2033.
- With a 48% market share, the United States is predicted to lead the industry in North America.
- South Asia is expected to increase at a 4.2% CAGR in terms of Hyperammonemia Treatment disbursement.
- By the end of 2033, glycerol phenylbutyrate is predicted to account for 35.5% of the segment.
- By the end of the projection period, hospital pharmacies will have a segment share of around 48%.
- Product demand is expected to rise as gene Treatment for hyperammonemia progresses.
“Advancements in gene Treatment and growing investments in Research & development for treatment of hyperammonemia will bolster product demand”, comments an FMI analyst
Get in Touch With Our Team For Discount@ https://www.futuremarketinsights.com/request-discount/rep-gb-16383
Competitive Landscape
The market is fragmented and moderately competitive. The strategies such as mergers and acquisitions adopted by major market players will boost the studied market growth. The major players in the market are: Bausch Health Companies, Inc., Recordati Rare Diseases Inc., Lucane Pharma SA, Acer Therapeutics, Ultragenyx Pharmaceutical Inc, Aeglea BioTherapeutics, Arcturus Therapeutics Holdings Inc., Orpharma Pty Ltd, Abbott Laboratories, and Selecta Biosciences, Inc. Some recent developments in this industry are as follows:
- Acer Therapeutics and Relief Therapeutics Holding AG, a biopharmaceutical company, agreed into a collaboration and licence agreement in January 2021 to develop and commercialise acer-001, a sodium Phenylbutyrate drug combination for the treatment of urea cycle diseases.
- Versantis AG announced in July 2022 that the US Food and Drug Administration (FDA) had classified VS-01, an ammonia clearance booster, as a rare paediatric disease designation for the treatment of urea cycle disorders.
- According to Acer Therapeutics Inc. and its collaborative partner, RELIEF THERAPEUTICS, in October 2021. (UCDs). The FDA accepted the submission of the New Drug Application (NDA) for the medication ACER-001 (sodium phenylbutyrate) for the treatment of patients with urea cycle disorders.
- In January 2021, Recordati Rare Diseases Inc. received the US Food and Drug Administration (FDA) approval for CARBAGLU for the treatment of acute hyperammonemia
More insights available:
North America is the largest hyperammonemia market due to the high prevalence of genetic disorders such as urea cycle disorders (UCD) in the region. The increasing awareness about these disorders and their treatment options, coupled with favorable reimbursement policies, is expected to drive the market growth in this region.
Request Customization of Report@ https://www.futuremarketinsights.com/customization-available/rep-gb-16383
Key Segments Profiled in the Hyperammonemia Treatment Market Industry Survey
By Treatment Type:
- Amino Acid Supplements
- Sodium Phenylbutyrate
- Glycerol Phenylbutyrate
- Sodium Benzoate
- Others
By Route of Administration:
- Oral
- Injectable
By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
About Future Market Insights, Inc.
Future Market Insights, Inc. (ESOMAR certified, Stevie Award – recipient market research organization and a member of Greater New York Chamber of Commerce) provides in-depth insights into governing factors elevating the demand in the market. It discloses opportunities that will favor the market growth in various segments on the basis of Source, Application, Sales Channel and End Use over the next 10-years.
Contact:
Future Market Insights, Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Browse All Reports: https://www.futuremarketinsights.com/reports
LinkedIn | Twitter | Blogs
